The Nonclinical Safety Assessment of a Novel Anti-CEACAM5 Antibody Exatecan Conjugate Predicts a Low Risk for Interstitial Lung Disease (ILD) in Patients—The Putative Mechanism Behind ILD
用户RdN6vXU76fqU
1个月前
102
10
已关闭
DOI: 10.1177/10915818241306039
文献链接: https://journals.sagepub.com/doi/10.1177/10915818241306039
其他信息:
出版社: SAGE Publications
作者: Willem N. Sloot; Elisa Bertotti; Manuela Onidi; Andrea Paoletti; Ilse De Salve; Patrizia Tavano; Enrico Vigna; Gundi Mueller
全文下载地址: https://journals.sagepub.com/doi/pdf/10.1177/10915818241306039